Subsequent biologic and targeted synthetic disease modifying anti rheumatic drugs after fulfilling difficult-to-treat rheumatoid arthritis criteria: a survival analysis.
Marta Novella NavarroVirginia Ruiz-EsquideNatalia López-JuanesChafik Alejandro ChacurIrene Monjo HenryLaura NuñoDiana PeiteadoAlejandro VillalbaElisa Fernández-FernandezMaría Sanz-JardónMónica KafatiRaimon SanmartíChamaida Plasencia-RodriguezAlejandro BalsaPublished in: Clinical rheumatology (2024)
Once patients met the D2TRA criteria, the subsequent line of b/tsDMARDs with the best survival rates were rituximab, JAKi and IL6Ri. Moreover, DAS28 at 6-months of treatment after D2T was an independent risk factor for drug discontinuation. Key Points • Rituximab, IL6Ri and JAKi have better retention rates in patients after fulfilling D2TRA criteria • Clinical disease activity in the first six months after fulfillment of D2TRA criteria is an independent risk factor of subsequent treatment survival.
Keyphrases
- rheumatoid arthritis
- disease activity
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- systemic lupus erythematosus
- ejection fraction
- ankylosing spondylitis
- diffuse large b cell lymphoma
- emergency department
- prognostic factors
- risk factors
- juvenile idiopathic arthritis
- patient reported outcomes
- adverse drug